CDC37 and cancer: Based on the observation that the silencing of Cdc37 sensitizes cancer cells to ATP-pocket binding Hsp90 inhibitors, combinations of the Hsp90/Cdc37 interface and ATP-pocket inhibitors could act synergistically [64].